MYIA
DNLI icon

Mount Yale Investment Advisors’s Denali Therapeutics DNLI Stock Holding History

Mount Yale Investment Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Buy
+8,343
New +$171K ﹤0.01% 1125
2025
Q3 		– Sell
-201
Closed -$2.81K – 901
2025
Q2 		$2.81K Buy
+201
New +$2.83K ﹤0.01% 1296

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mount Yale Investment Advisors's DNLI Position: Q2 2026 in Review

Mount Yale Investment Advisors opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 8,343 shares worth $215K. The stake represents ﹤0.01% of the portfolio and ranks #1125 among its holdings. This is a return to the name: Mount Yale Investment Advisors previously reported a position in DNLI as recently as Q2 2025.

Mount Yale Investment Advisors first reported a position in DNLI in Q2 2025 and has held it in 2 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Mount Yale Investment Advisors held 8,343 shares of Denali Therapeutics worth $215K as of Q2 2026.
  • Denali Therapeutics was a new Mount Yale Investment Advisors position in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Mount Yale Investment Advisors's portfolio in Q2 2026, its #1125 holding.
  • Mount Yale Investment Advisors first reported a position in Denali Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.